Disease · MONDO_0000447
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 12 of 12
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01670110 | Pasireotide LAR in Severe Polycystic Liver Disease | Phase 2 | 48 | 2020-03-02 | Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease | PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00426153 | Octreotide in Severe Polycystic Liver Disease | Phase 2/3 | 42 | 2012-11-21 | Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain | OCTREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00934791 | Polycystic Liver Disease in Kidney Transplant | Not applicable | 2 | 2013-03-08 | Polycystic Liver Disease | SIROLIMUS, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01616927 | Study of Lanreotide to Treat Polycystic Kidney Disease | Phase 3 | 300 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | LANREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05281328 | A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Phase 2/3 | 71 | Polycystic Liver Disease | OCTREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01315795 | Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease | Phase 2/3 | 59 | Polycystic Liver Disease | LANREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00771888 | Open-Label Extension of LOCKCYST Trial | Phase 2/3 | 54 | Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney, Autosomal Dominant | LANREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01157858 | Everolimus and LongActing Octreotide Trial in Polycystic Livers | Phase 2 | 44 | Polycystic Liver Disease | EVEROLIMUS, OCTREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01354405 | Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) | 43 | Polycystic Liver Disease | LANREOTIDE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05478083 | A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease | Phase 2 | 36 | Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney | LEUPROLIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02119052 | Effects of Somatostatin on Liver in ADPKD | Phase 2/3 | 35 | Autosomal Dominant Polycystic Kidney Disease | OCTREOTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02021110 | Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease | Phase 2 | 34 | Polycystic Liver Disease, Polycystic Kidney, Autosomal Dominant | URSODIOL | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000447/trials